Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : Results of FACTS1-international

作者: David M Reid , David Hosking , David Kendler , Maria L Brandi , John D Wark

DOI: 10.2165/00044011-200626020-00002

关键词: Femoral neckOsteoporosisBone densityBone remodelingMedicineAlendronic acidRisedronic acidTolerabilityUrologyBone mineral

摘要: Background: The objective of the study was to evaluate effects alendronic acid once weekly relative risedronic on bone mineral density (BMD), markers turnover and tolerability in treatment osteoporosis postmenopausal women. Methods: This a randomised, double-masked, double-dummy multicentre international (75 centres 27 countries Europe, Americas Asia-Pacific). A total 1303 women were screened 936 with low (T-score ≤−2.0 at spine, hip trochanter, or femoral neck) randomised; 91% (n = 854) completed study. Patients randomised either active 70mg (Fosamax®) placebo identical 35mg (Actonel®) for 12 months. primary efficacy endpoint percentage change from baseline trochanter BMD Secondary endpoints included lumbar neck BMD; biochemical (including serum bone-specific alkaline phosphatase [BSAP] urinary type I collagen N-telopeptides [NTx]); safety as assessed by reporting adverse experiences. Results: Alendronic produced greater increases than did months all sites measured. Mean month 3.56% 2.71% groups, respectively (treatment difference [95% CI]: 0.83% [0.22, 1.45; p 0.008]). (p 0.002, < 0.001, 0.039, respectively). Increases compared also significantly 6 hip. There reduction acid: NTx decreased 58% 47% 0.001); BSAP 45% 34% 0.001). Overall upper gastrointestinal similar both agents. Conclusions: spine reductions weekly. Both agents well tolerated no significant Clinicians should consider these results when making decisions osteoporosis.

参考文章(34)
Nelson B. Watts, Cyrus Cooper, Robert Lindsay, Richard Eastell, Michael D. Manhart, Ian P. Barton, Tjeerd-Pieter van Staa, Jonathan D. Adachi, Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk. Journal of Clinical Densitometry. ,vol. 7, pp. 255- 261 ,(2004) , 10.1385/JCD:7:3:255
S.R. Cummings, W. Browner, S.R. Cummings, D.M. Black, M.C. Nevitt, W. Browner, H.K. Genant, J. Cauley, K. Ensrud, J. Scott, T.M. Vogt, Bone density at various sites for prediction of hip fractures The Lancet. ,vol. 341, pp. 72- 75 ,(1993) , 10.1016/0140-6736(93)92555-8
Marc C. Hochberg, Susan Greenspan, Richard D. Wasnich, Paul Miller, Desmond E. Thompson, Philip D. Ross, Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. The Journal of Clinical Endocrinology and Metabolism. ,vol. 87, pp. 1586- 1592 ,(2002) , 10.1210/JCEM.87.4.8415
R Eastell, I Barton, Ra Hannon, A Chines, P Garnero, Pd Delmas, Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate Journal of Bone and Mineral Research. ,vol. 18, pp. 1051- 1056 ,(2003) , 10.1359/JBMR.2003.18.6.1051
Ann Cranney, Gordon Guyatt, Lauren Griffith, George Wells, Peter Tugwell, Clifford Rosen, , , Meta-analyses of Therapies for Postmenopausal Osteoporosis. IX: Summary of Meta-Analyses of Therapies for Postmenopausal Osteoporosis Endocrine Reviews. ,vol. 23, pp. 570- 578 ,(2002) , 10.1210/ER.2001-9002
C. H. Chesnut, C. J. Rosen, Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. Journal of Bone and Mineral Research. ,vol. 16, pp. 2163- 2172 ,(2001) , 10.1359/JBMR.2001.16.12.2163
Dennis M Black, Desmond E Thompson, Douglas C Bauer, Kris Ensrud, Thomas Musliner, Marc C Hochberg, Michael C Nevitt, Shailaja Suryawanshi, Steven R Cummings, FIT Research Group, None, Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial The Journal of Clinical Endocrinology and Metabolism. ,vol. 85, pp. 4118- 4124 ,(2000) , 10.1210/JCEM.85.11.6953
Silvina Levis, Sara A. Quandt, Desmond Thompson, Jean Scott, Diane L. Schneider, Philip D. Ross, Dennis Black, Shailaja Suryawanshi, Marc Hochberg, John Yates, The FIT Research Group, Alendronate Reduces the Risk of Multiple Symptomatic Fractures: Results from the Fracture Intervention Trial Journal of the American Geriatrics Society. ,vol. 50, pp. 409- 415 ,(2002) , 10.1046/J.1532-5415.2002.50102.X